tiprankstipranks
Advertisement
Advertisement

BIOA Stock Latest News

BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
RatingsBioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained
18d ago
BIOA
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
PremiumCompany Announcements
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
1M ago
BIOA
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
PremiumThe Fly
BioAge Labs doses first participant in QUELL-CV trial of BGE-102
1M ago
BIOA
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
PremiumCompany Announcements
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
1M ago
8K
BIOA
BioAge Labs initiated with a Buy at Roth Capital
PremiumThe Fly
BioAge Labs initiated with a Buy at Roth Capital
2M ago
BIOA
AMD, Under Armour downgraded: Wall Street’s top analyst calls
PremiumThe FlyAMD, Under Armour downgraded: Wall Street’s top analyst calls
2M ago
UA
AMD
BioAge Labs initiated with a Buy at BTIG
Premium
The Fly
BioAge Labs initiated with a Buy at BTIG
2M ago
BIOA
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
Premium
Ratings
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
3M ago
BIOA
BioAge Labs reports Q1 EPS (52c), consensus (63c)
PremiumThe Fly
BioAge Labs reports Q1 EPS (52c), consensus (63c)
3M ago
BIOA
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
PremiumRatings
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
3M ago
BIOA
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
PremiumThe Fly
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
3M ago
BIOA
BioAge Labs initiated with a Buy at Needham
PremiumThe Fly
BioAge Labs initiated with a Buy at Needham
4M ago
BIOA
BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating
PremiumRatingsBioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating
4M ago
BIOA
BioAge Labs files automatic mixed securities shelf
Premium
The Fly
BioAge Labs files automatic mixed securities shelf
4M ago
BIOA
BioAge Highlights BGE-102 Progress and Financial Strength
Premium
Company Announcements
BioAge Highlights BGE-102 Progress and Financial Strength
4M ago
8K
BIOA
BIOA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
BIOA Earnings this Week: How Will it Perform?
4M ago
BIOA
BioAge Labs price target raised to $52 from $15 at Citi
PremiumThe Fly
BioAge Labs price target raised to $52 from $15 at Citi
5M ago
BIOA
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
PremiumRatings
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
5M ago
BIOA
BioAge Labs initiated with an Outperform at Oppenheimer
PremiumThe Fly
BioAge Labs initiated with an Outperform at Oppenheimer
5M ago
BIOA
VTYX
Midday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
PremiumThe FlyMidday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
5M ago
T
CHT
BioAge Labs upgraded to Buy from Hold at Jefferies
Premium
The Fly
BioAge Labs upgraded to Buy from Hold at Jefferies
5M ago
BIOA
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
Premium
The Fly
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
6M ago
BIOA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >